Status:
COMPLETED
Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborating Sponsors:
Dongyang People's Hospital
Haiyan People's Hospital
Conditions:
Intravenous Alteplase Thrombolysis
Neurological Improving
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Previous clinical studies have confirmed that revascularization or recanalization rate after intravenous thrombolysis is closely related to the formation of thrombus, which also results in poor neurol...
Eligibility Criteria
Inclusion
- Age over 18 years old, clinically diagnosed as acute ischemic stroke;
- in accordance with the indications for intravenous thrombolysis;
- The patient or family member signs an informed consent form.
Exclusion
- Patients with transient ischemic attack;
- Imaging examination of patients with cerebral hemorrhage
- patients with cerebral arteritis
- ALT, AST ≥ 3 times the upper limit of normal value, Cr ≥ 1.5 times the upper limit of normal value
- There is a tendency to bleed, and severe bleeding has occurred within 3 months
- Patients with ginkgo drugs, alcohol, glycerol allergies or allergies
- Patients with pregnancy plans, pregnancy and breastfeeding
- Patients who participated in other drug clinical studies in the past month
- Patients considered by the investigator to be unfit to participate in the clinical study (eg, mental, abnormal, etc.)
Key Trial Info
Start Date :
July 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
1189 Patients enrolled
Trial Details
Trial ID
NCT03772847
Start Date
July 31 2018
End Date
December 31 2021
Last Update
May 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Min Lou
Hangzhou, Zhejiang, China, 310000